Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Quirine C. van Rossum"'
Autor:
Sanne M. Buijs, C. Louwrens Braal, Stefan A. J. Buck, Noud F. van Maanen, Lonneke M. van der Meijden-Erkelens, Heleen A. Kuijper-Tissot van Patot, Esther Oomen-de Hoop, Lotte Saes, Sophia J. van den Boogerd, Liesbeth E. M. Struik, Quirine C. van Rossum-Schornagel, Ron H. J. Mathijssen, Stijn L. W. Koolen, Agnes Jager
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-7 (2023)
Abstract Tamoxifen may lead to bothersome side effects contributing to non-compliance and decreased quality of life. Patients searching for relief are increasingly turning to cannabinoids such as CBD-oil. However, CBD-oil might affect tamoxifen pharm
Externí odkaz:
https://doaj.org/article/270e89bb85c04654be454a2dba613f34
Autor:
Stefan A. J. Buck, C. Louwrens Braal, Maaike M. Hofman, Esther Oomen-de Hoop, Peter de Bruijn, Inge M. Ghobadi Moghaddam-Helmantel, Koen G. A. M. Hussaarts, Mijntje B. Vastbinder, Quirine C. van Rossum-Schornagel, Ron H. N. van Schaik, Agnes Jager, Stijn L. W. Koolen, Ron H. J. Mathijssen
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Introduction: In breast cancer patients treated with the anti-estrogen tamoxifen, low concentrations of the active metabolite endoxifen are associated with more disease recurrence. We hypothesized that we could increase endoxifen concentrations by in
Externí odkaz:
https://doaj.org/article/258552e485654475a839962a4fd6a115
Autor:
Martine F Thijs-Visser, Mijntje B. Vastbinder, Liesbeth E. M. Struik, Hanneke J. M. Zuetenhorst, Justin D. Westenberg, C. Louwrens Braal, Koen M. W. T. Lommen, Ron H.J. Mathijssen, Robbert J. van Alphen, Stijn L.W. Koolen, Agnes Jager, Esther Oomen-de Hoop, Peter de Bruijn, Quirine C. van Rossum-Schornagel
Publikováno v:
Clinical Pharmacokinetics, 61(4), 527-537. Adis
Background: Endoxifen is the most important active metabolite of tamoxifen. Several retrospective studies have suggested a minimal or threshold endoxifen systemic concentration of 14–16 nM is required for a lower recurrence rate. The aim of this st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2284dea60a5044e1d335b11be933342
https://pure.eur.nl/en/publications/b67beed5-f844-4074-a150-898c7b3e6de5
https://pure.eur.nl/en/publications/b67beed5-f844-4074-a150-898c7b3e6de5
Autor:
C Louwrens, Braal, Agnes, Jager, Esther Oomen-de, Hoop, Justin D, Westenberg, Koen M W T, Lommen, Peter, de Bruijn, Mijntje B, Vastbinder, Quirine C, van Rossum-Schornagel, Martine F, Thijs-Visser, Robbert J, van Alphen, Liesbeth E M, Struik, Hanneke J M, Zuetenhorst, Ron H J, Mathijssen, Stijn L W, Koolen
Publikováno v:
Clinical pharmacokinetics. 61(4)
Endoxifen is the most important active metabolite of tamoxifen. Several retrospective studies have suggested a minimal or threshold endoxifen systemic concentration of 14-16 nM is required for a lower recurrence rate. The aim of this study was to inv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cc5759601dbbcfda1b6f119837d89c71
https://pubmed.ncbi.nlm.nih.gov/34786650
https://pubmed.ncbi.nlm.nih.gov/34786650
Autor:
Mijntje B. Vastbinder, Agnes Jager, Roelof W F van Leeuwen, Leonie J van Harten, Esther Oomen-de Hoop, Leontine E.A. Spierings, Ron H.J. Mathijssen, Teun van Gelder, Koen G A M Hussaarts, Stan Berghuis, Daan P. Hurkmans, Robbert J. van Alphen, Ron H.N. van Schaik, Quirine C. van Rossum-Schornagel
Publikováno v:
Cancers
Volume 11
Issue 3
Cancers, 11(3):403. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, Vol 11, Iss 3, p 403 (2019)
Volume 11
Issue 3
Cancers, 11(3):403. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, Vol 11, Iss 3, p 403 (2019)
Tamoxifen is a prodrug that is primarily metabolized into the pharmacologically active metabolite endoxifen and eventually into inactive metabolites. The herb curcumin may increase endoxifen exposure by affecting phase II metabolism. We compared endo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5a6300c082c1dba95fe98d7a4423dc4
Autor:
Hiltje de Graaf, Aafke H. Honkoop, Joan B. Heijns, Paul Hamberg, Steffen M de Groot, Agnes Jager, Stefan Sleijfer, Johanneke E.A. Portielje, Sabine C. Linn, Judith R. Kroep, Jan C. Drooger, Albert J. ten Tije, Frans L. G. Erdkamp, Harm van Tinteren, Quirine C. van Rossum-Schornagel, A. Elise van Leeuwen-Stok, Alex L. T. Imholz
Publikováno v:
Cancer. 122:2961-2970
textabstractBACKGROUND: To explore the role of bevacizumab and a chemotherapy-free approach, the authors evaluated the combination of bevacizumab, trastuzumab, and paclitaxel (HAT) and the regimen of trastuzumab and bevacizumab (HA) with the addition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59c6df2711af147df29d85205a65c6b8
https://doi.org/10.1002/cncr.30141
https://doi.org/10.1002/cncr.30141
Autor:
Jan C, Drooger, Harm, van Tinteren, Steffen M, de Groot, Albert J, Ten Tije, Hiltje, de Graaf, Johanneke E A, Portielje, Agnes, Jager, Aafke, Honkoop, Sabine C, Linn, Judith R, Kroep, Frans L G, Erdkamp, Paul, Hamberg, Alex L T, Imholz, Quirine C, van Rossum-Schornagel, Joan B, Heijns, A Elise, van Leeuwen-Stok, Stefan, Sleijfer
Publikováno v:
Cancer. 122(19)
To explore the role of bevacizumab and a chemotherapy-free approach, the authors evaluated the combination of bevacizumab, trastuzumab, and paclitaxel (HAT) and the regimen of trastuzumab and bevacizumab (HA) with the addition of paclitaxel after pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7eed18d8643ac3859ea51cea2202face
https://pubmed.ncbi.nlm.nih.gov/27315546
https://pubmed.ncbi.nlm.nih.gov/27315546
Autor:
Daan P. Hurkmans, Quirine C. van Rossum, Agnes Jager, Esther Oomen-de Hoop, Robbert J. van Alphen, Gerardus Hussaarts, Mijntje B. Vastbinder, Leonie J van Harten, Roelof W F van Leeuwen, Stan Berghuis, Ron H.N. van Schaik, Leontine E.A. Spierings, Teun van Gelder, Ron H.J. Mathijssen
Publikováno v:
Journal of Clinical Oncology. 36:2572-2572
2572Background: Tamoxifen is extensively used as endocrine therapy for breast cancer. It is a prodrug that is primarily metabolized by CYP2D6 and CYP3A4, particular into endoxifen. In daily practic...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67894eebc028770672ac11e1a907dcac
https://doi.org/10.1200/jco.2018.36.15_suppl.2572
https://doi.org/10.1200/jco.2018.36.15_suppl.2572